Greenwich LifeSciences FLAMINGO-01 GP2 Vaccine Drives 4x Delayed-Type Hypersensitivity Response in Open-Label Data
Greenwich LifeSciences presented FLAMINGO-01 Phase III open-label data at AACR 2026 showing GLSI-100 (the 9-amino-acid GP2 HER2 peptide plus GM-CSF adjuvant) produced a ~4x increase in delayed-type hypersensitivity to GP2 across 247 non-HLA-A*02 patients — from 5.2% at baseline to 20.4% at months 4-6 (p<0.001). GP2 is the C-terminal transmembrane fragment of the HER2/neu protein.